President and CEO
Enrico Domenici is Professor at the Centre for Integrative Biology University of Trento, where he leads the Neurogenomic Biomarker Unit and coordinates the MSc in Quantitative and Computational Biology. He joined the academia after 25 years of experience in Drug Discovery, where he has led several projects in different therapeutic areas. Since 2000, his main focus is the discovery and validation of biomarkers in neuroscience by integrating genomics and proteomics in preclinical and clinical context. He recently served as Molecular Medicine Director (GSK Research Centre, Verona, 2000-2010), Biomarker&Pathway Analysis Area Head and Biomarker Experimental Medicine Leader (Roche Innovation Centre, Basel, 2010-2015). During his scientific career, Enrico has established several academia-industry collaborations and precompetitive consortia. He is a member of advisory and scientific boards and is the author of over 70 peer-reviewed original publications, as well as many book chapters. Enrico graduated in Biology at the University of Pisa and got a PhD in Chemistry at the Scuola Normale Superiore, Pisa.
Microsoft Research Cambridge
Luca Cardelli has a Ph.D. in computer science from the University of Edinburgh. He worked at Bell Labs, Murray Hill, from 1982 to 1985, and at Digital Equipment Corporation, Systems Research Center in Palo Alto, from 1985 to 1997, before assuming a position at Microsoft Research, in Cambridge UK, where he was head of the Programming Principles and Tools and Security groups until 2012. Since 2014 he is also a Royal Society Research Professor at the University of Oxford. His main interests are in programming languages and concurrency, and more recently in programmable biology and nanotechnology. He is a Fellow of the Royal Society, a Fellow of the Association for Computing Machinery, an Elected Member of the Academia Europaea, and an Elected Member of the Association Internationale pour les Technologies Objets.
University of Pisa
Pierpaolo Degano is full Professor in Computer Science; head of the PhD programme and of the Italian Committee of PhD programmes. he served as head of the CS department in Pisa; as chairman the Italian Association of the Professors of CS; as chairman of many conferences and editor of their proceedings; as a member of steering committees of research association and of several international committees for evaluating academic institutions, projects, researchers and professors; co-founder of the IFIP TC1 WG 1.7 on Theo. Found. of Security Analysis & Design and of the POST conference. Prof. Degano is member of the Editorial Board of Theo. Comp. Sci.-C, of the Monographs & Texts in Theo. Comp. Sci., and of Mondo Digitale. His main research topics include programming language semantics, security and computational biology, on which he published more than 200 papers. He participated, often as project leader, in several research projects.
Fabio Santini is Developer Experience and Evangelism Lead in Microsoft Italy, he leads the commitment towards youth, developers and IT professionals in defining activities and strategies than aim at providing the technological tools that are necessary for translating ideas into plans of action. His team focuses on innovation as a mean of entrepreneurship. Fabio Santini spent 14 years in Microsoft, before his last role he was Server & Tools (now Cloud & Enterprise) Director. He was previously part of Enterprise and Partner division as a Business Productivity Sales Manager, Developer Evangelist for Developer Platform Evangelism Division and lead the Partner Technology Advisor and Partner Strategy and Program Teams for SMS&P Before Microsoft he was R&D Manager in a software house. He loves to spend free time with his 2 sons, play football and go to the cinema.
Founder and Chief Scientific Officer
Corrado Priami is professor of computer science at the University of Pisa, director of the Pisa node of the Stanford SPARK Global initiative, and has 20+ years of academic and industrial experience in the application of computational technology for pharma and food companies. He is the founder of COSBI, that he led 12+ years as President and CEO. He managed projects for over euro 30 million (about euro 16 million for industrial projects). He served in the Senate of the University of Verona, in the BoD of the University of Trento, in the BoD of the Trento School of Management and in the BoD of COSBI as chairman of the board. He published over 200 scientific papers, gave more than 110 invited talks and lectures, regularly serves in advisory and scientific boards (including the Stanford SPARK program) as well as in reviewing panels for international funding agencies and institutions. He supervised more than 100 people (students, PhD students, Post-Docs) of which about 40 are now in senior or research positions in academia and industry. He got a master and PhD in computer science from the University of Pisa. He was post-doc with a competitive EU Marie Curie Grant at the Ecole Normale Superiéure in Paris (1996-97), researcher and associate professor at the University of Verona (1997-2001), visiting scholar at Microsoft Corp (2004), visiting professor at Stanford University (2016-17), professor at the University of Trento (2001-2017).
Karim Azer is the head of the quantitative systems pharmacology (QSP) and DMPK modeling at the Bill & Melinda Gates Medical Research Institute. His work is focused on leveraging the spectrum of bioinformatics, systems biology, QSP and DMPK modeling approaches, and data analytics, to address translational medicine needs of the institute, in the areas of tuberculosis, malaria, and diarrheal and enteric diseases. Karim’s efforts are also dedicated to the development of supportive computational and mathematical approaches and pipelines to enable robust in-silico simulations and visualizations of models and model outputs. Karim received his PhD in Applied Mathematics from the Courant Institute of Mathematical Sciences at NYU, and holds an M.S. in Applied Mathematics from Courant Institute at NYU, and B.S. degrees in Mathematics and Computer Science from Rutgers University. He has worked in the pharmaceutical industry for over 20 years, employing a wide variety of modeling, both mechanistic and empirical, and computer science approaches to address drug discovery and development questions in R&D. Previously at Sanofi, he formed and headed the quantitative systems pharmacology group, supporting programs across several disease areas, including immunology, rare diseases, cardiovascular and oncology. He also led the development of technical capabilities in support of model development, calibration, qualification and simulation, in collaboration with academic partners and Institutes. Prior to Sanofi, he was at Merck, where he established a quantitative group spanning a broad range of computational approaches to drug discovery, development and translational medicine, including both mechanistic and empirical models, image and signal processing, data analytics, and high performance computing, and where he led modeling efforts in support of early clinical development and translational medicine programs. He has served on a number of professional societies such as American College of Clinical Pharmacology (ACCP), American Society of Mechanical Engineering (ASME), IEEE, Society for Industrial and Applied Mathematics (SIAM), and International Society of Pharmacometrics (ISOP), and continues to be active in the community. He has publications in the areas of applied mathematics, modeling applications and methodologies in drug discovery and development, image and signal processing, and data analytics.
Pier Paolo Di Fiore
Fondazione IFOM - Istituto FIRC di Oncologia Molecolare
Pier Paolo Di Fiore is group leader at IFOM, an internationally competitive research institute in Milan, which he founded in 1998, and Director of the Molecular Medicine Program at IEO, a leading cancer care center in Milan. He is also Full Professor of General Pathology at the University of Milan, and co-founder of the post- graduate European School of Molecular Medicine. Di Fiore has dedicated his scientific career to deciphering the molecular mechanisms of cellular transformation, with emphasis on growth factor receptor signaling, endocytosis and stem cell biology. He recently uncovered a link between endocytosis and cancer by demonstrating that the endocytic protein and cell fate determinant, Numb, is a key tumor suppressor protein in breast cancer that functions at the level of the SC compartment. He has also identified several genomic signatures that form the basis of new clinical tools for the early detection of cancer and prognosis prediction.
Larry C. Wienkers received his Ph.D. in Medicinal Chemistry from University of Washington in 1993 under the direction of Dr William F. Trager. He did postdoctoral work in the department of Drug Metabolism at the Upjohn Company and subsequently joined the company as a Research Scientist 1995. In 1998, Larry became Director of Drug Metabolism Enabling Technologies at Pharmacia & Upjohn and in 2002 became Executive Director of Pharmacokinetics, Dynamics and Metabolism at Pfizer. In 2004 Larry moved to Amgen and is currently Vice President of the department of Pharmacokinetics and Drug Metabolism. He an American Association of Pharmaceutical Scientists (AAPS) Fellow and serves as a member of the University Of Washington School Of Pharmacy Corporate Advisory Board. Larry's current research interests are focused on exploring bioactivation pathways associated with small molecule drug metabolism with particular focus on the prospective application of this information to predict drug-drug interactions in the clinic. To this end, his group applies a multidisciplinary approach using organic chemistry, biochemistry and biophysical techniques to study cytochrome P450 mechanism based inhibition and the characterization of biotransformation pathways of novel therapeutics.
University of Trento
Paolo Collini has been the Rector of the University of Trento since 1 st April 2015, after being Vice Rector and Pro- Rector for Teaching activities. He has been a member of the Academic Senate for various mandates and he was the Dean of the Faculty of Economics. Further, he has been the Director of the School of International Studies and Vice Director of the Department of Computer Science and Business Studies. He graduated in Economics at the University Ca’ Foscari, he then attended a Master of Science in Business Administration at the Boston University School of Management and then a PhD course in Business Economics at the University of Venice. He has been full Professor at the University of Trento since 2009. He has been active with many Italian and international universities and member of various important associations, such as AIDEA (Italian Academy of Business Economics), SIDREA (Italian Society of Professors of Business Administration and Economics), SIR (Italian Society of the History of Business Administration) and AIDEA - Giovani (of which he has been President). As for his scientific publishing activity, he is member of important editorial boards and scientific committees.
Jim Karkanias is a Partner at Microsoft, leading Program Management for Information Management and Machine Learning in the Cloud + Enterprise Division at Microsoft. His background spans science (neuroscience), engineering (bioengineering, code development), technology (neural nets, machine learning, robotics, quantum physics) and business (including a start-up in the 90s, head of clinical operations for the human health division at Merck, etc.) – and now he is combining a bit of all of that at Microsoft. He joined Microsoft in 2006 to apply his industry expertise to a new venture – the Health Solutions Group – which aimed to revolutionize healthcare through paradigm shifting approaches that integrate next generation business, process, and technology. Jim now leads Program Management for Microsoft Applied Technology in C+E, an entire division at Microsoft dedicated to - through data, services, and machine learning - activating the business value trapped in your organization.